SPOREs : Organ-Specific SPORE Programs : Breast

[ SPOREs: Brain | Breast | GI | GU | GYN | Head and Neck | Leukemia | Lung | Lymphoma | Myeloma | Ovarian | Pancreatic | Prostate | Skin ]

Breast SPOREs

Breast cancer is the most common form of cancer (with the exception of non-melanoma skin cancers) diagnosed in women in the United States and is second only to lung cancer in cancer deaths. Approximately 212,920 new invasive breast cancers will be identified in women in the year 2006 and about 40,970 deaths were attributed to this disease. During the course of her lifetime, a woman has a one in eight chance of developing breast cancer. Much progress has been made over the past decade in identifying hereditary factors (e.g., the BRCA1/2 predisposition genes), as well as novel therapeutic and preventative agents for breast cancer. The potential for rapidly moving laboratory discoveries into the clinic in this particular cancer site is enormous. The Breast Cancer SPORE program has grown steadily from 1992, when four sites were funded, to the present time with ten sites. The spectrum of studies supported by these grants includes the development of novel agents (e.g., liposomes, small molecule inhibitors, anti-estrogens, retinoids, angiogenic inhibitors, vaccines, radioisotopes, antibodies), technologies (e.g., microarrays, database mining), and markers (i.e., newly identified breast cancer genes/proteins) for the better diagnosis, prognosis, screening, prevention, and treatment of breast cancer.

To view the associated abstract, click on the name/address below.

The page is maintained by: Website Contact